Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Dermatological Treatment"
DOI: 10.1080/09546634.2022.2116266
Abstract: Abstract Objective To describe real-world baseline characteristics and patient-reported outcomes (PROs) at 6-month and 12-month follow-up visits among patients with psoriasis who initiated and maintained secukinumab, stratified by prior exposure to biologics. Methods This real-world… read more here.
Keywords: biologic naive; patients psoriasis; month follow; month ... See more keywords
P116 Patient characteristics of biologic-experienced and biologic-naive patients with chronic plaque psoriasis receiving bimekizumab
Sign Up to like & getrecommendations! Published in 2025 at "British Journal of Dermatology"
DOI: 10.1093/bjd/ljaf085.144
Abstract: The British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) is a prospective, observational cohort that records real-world psoriasis data in the UK and Ireland. Bimekizumab is a monoclonal immunoglobulin G1 antibody biologic that targets… read more here.
Keywords: biologic experienced; biologic naive; dermatology; experienced biologic ... See more keywords
Real-world Clinical Effectiveness and Safety of Vedolizumab and Adalimumab in Biologic-naive Patients With Crohn’s Disease
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Gastroenterology"
DOI: 10.1097/mcg.0000000000002056
Abstract: Goals: This study evaluated the real-world effectiveness and safety of vedolizumab versus adalimumab over 12 months of treatment in biologic-naive patients with Crohn’s disease (CD), using data from the EVOLVE study. Background: A comparison of… read more here.
Keywords: biologic naive; real world; vedolizumab; naive patients ... See more keywords